Diagnosis and Prevention of Pneumococcal Disease

  • Hanna Nohynek
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 582)


Streptococcus Pneumoniae Acute Otitis Medium Invasive Pneumococcal Disease Pneumococcal Disease Pneumococcal Conjugate Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Barzilay, E.J., O’Brien, K.L., Kwok, Y.S., Hoekstra, R.M., Zell, E.R., Reid, R., Santosham, M., Whitney, C.G., Feikin, D.R. (2005). Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. Vaccine Sep 30; (Epub).Google Scholar
  2. Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., Elvin, L., Ensor, K.M., Hackell, J., Siber, G., Malinoski, F., Madore, D., Chang, I., Kohberger, R., Watson, W., Austrian, R., Edwards, K. (2000). Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19:187–95.PubMedCrossRefGoogle Scholar
  3. Black, S.B., Shinefield, H.R., Ling, S., Hansen, J., Fireman, B., Spring, D., Noyes, J., Lewis, E., Ray, P., Lee, J., Hackell, J. (2002). Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21:810–15.PubMedCrossRefGoogle Scholar
  4. Centers for Disease Control and Prevention (CDC) (2005). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998–2003. MMWR Morb. Mortal. Wkly Rep. 54:893–7.Google Scholar
  5. Cherian, T., Mulholland, E.K., Carlin, J.B., Ostensen, H., Amin, R., de Campo, M., Greenberg, D., Lagos, R., Lucero, M., Madhi, S.A., O’Brien, K.L., Obaro, S., Steinhoff, M.C. (2005). Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull WHO. 83:353–9.PubMedGoogle Scholar
  6. Cutts, F.T., Zaman, S.M., Enwere, G., ym. (2005). Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 365:1139–46.PubMedCrossRefGoogle Scholar
  7. Dagan, R. (2004). The potential of pneumococcal conjugate vaccines to reduce antibiotic resistance. In: Pollard, A.J., McCracken, G.H., and Finn, A. (eds.) Hot topics in infection and immunity in children. Advances in Experimental Medicine and Biology, Volume 549. Kluwer Academic/Plenum Publishers, New York, pp. 211–19.Google Scholar
  8. Dagan, R., Shriker, O., Hazan, I., Leibovitz, E., Greenberg, D., Schlaeffer, F., Levy, R. (1998). Prospective study to determine clinical relevance of detection of pneumococcal DNA in sera of children by PCR. J. Clin. Microbiol. 36:669–73.PubMedGoogle Scholar
  9. Dagan, R., Melamed, R., Muallem, M., Piglansky, L., Greenberg, D., Abramson, O., Mendelman, P.M., Bohidar, N., Yagupsky, P. (1996). Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J. Infect. Dis. 174:1271–8.PubMedGoogle Scholar
  10. Eskola, J., Kilpi, T., Palmu, A., Jokinen, J., Haapakoski, J., Herva, E., Takala, A., Käyhty, H., Karma, P., Kohberger, R., Siber, G., Mäkelä, P.H.; Finnish Otitis Media Study Group. (2001). Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403–9.PubMedCrossRefGoogle Scholar
  11. Eskola, J., Black, S.B., and Shinefield, H. (2004). Pneumococcal conjugate vaccine. In: Plotkin, S., Orenstein, W. (eds.), Vaccines, 4th edition, Saunders, Philadelphia, pp. 589–624.Google Scholar
  12. Fedson, D.S., and Musher, D.M. (2004). Pneumococcal polysaccharide vaccine. In: Plotkin, S., Orenstein, W. (eds.), Vaccines, 4th edition, Saunders, Philadelphia, pp. 529–88.Google Scholar
  13. Greenwood, B. (2005). Interpreting vaccine efficacy. Clin. Infect. Dis. 40:1519–20.PubMedCrossRefGoogle Scholar
  14. Hausdorff, W.P., Feikin, D.R., Klugman, K.P. (2005). Epidemiological differences among pneumococcal serotypes. Lancet Infect. Dis. 5:83–93.PubMedGoogle Scholar
  15. Hausdorff, W.P. (2002). Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur. J. Pediatr. 161Suppl 2:S135–9.PubMedCrossRefGoogle Scholar
  16. Huttunen, T., Teppo, A.M., Lupisan, S., Ruutu, P., Nohynek, H. (2003). Correlation between the severity of infectious diseases in children and the ratio of serum amyloid A protein and C-reactive protein. Scand. J. Infect. Dis. 35:488–90.PubMedCrossRefGoogle Scholar
  17. Kilpi, T., Åhman, H., Jokinen, J., Lankinen, K.S., Palmu, A., Savolainen, H., Grönholm, M., Leinonen, M., Hovi, T., Eskola, J., Käyhty, H., Bohidar, N., Sadoff, J.C., Mäkelä, P.H.; Finnish Otitis Media Study Group. (2003). Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37:1155–64.PubMedCrossRefGoogle Scholar
  18. Kleemola, M., Nokso-Koivisto, J., Herva, E., Syrjänen, R., Lahdenkari, M., Kilpi, T., Hovi, T. (2005). Is there any specific association between respiratory viruses and bacteria in acute otitis media of young children? J. Infect. Jun 28; ••.Google Scholar
  19. Klugman, K.P., Madhi, S.A., Huebner, R.E., Kohberger, R., Mbelle, N., Pierce, N., and Vaccine Trialists Group. (2003). A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:1341–8.PubMedCrossRefGoogle Scholar
  20. Lankinen, K.S., Ruutu, P., Nohynek, H., Lucero, M., Paton, J.C., Leinonen, M. (1999). Pneumococcal conjugate vaccine. In: Plotkin, S., Orenstein, W. (eds.), Vaccines, 4th edition, Saunders, Philadelphia, pp. 589–624 pneumonia diagnosis by demonstration of pneumolysin antibodies in precipitated immune complexes: a study in 350 Philippine children with acute lower respiratory infection. Scand. J. Infect. Dis. 31:155–61.Google Scholar
  21. Levine, O.S., Cherian, T., Shah, R., and Batson, A. (2004). PneumoADIP: an example of translational research to accelerate pneumococcal vaccination in developing countries. J. Health Popul. Nutr. 22:268–74.PubMedGoogle Scholar
  22. Levine, O.S., Lagos, R., Munoz, A., Villaroel, J., Alvarez, A.M., Abrego, P., and Levine, M.M. (1999). Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr. Infect. Dis. J. 18:1060–4.PubMedCrossRefGoogle Scholar
  23. Lexau, C.A., Lynfield, R., Danila, R., Pilishvili, T., Facklam, R., Farley, M.M., Harrison, L.H., Schaffner, W., Reingold, A., Bennett, N.M., Hadler, J., Cieslak, P.R., Whitney, C.G.; and Active Bacterial Core Surveillance Team. (2005). Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J. Amer. Med. Ass. 294:2043–51.CrossRefGoogle Scholar
  24. Lipsitch, M. (2001). Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes. Am. J. Epidemiol. 154:85–92.PubMedCrossRefGoogle Scholar
  25. Lieu, T.A., Ray, G.T., Black, S.B., Butler, J.C., Klein, J.O., Breiman, R.F., Miller, M.A., Shinefield, H.R. (2000). Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. J. Amer. Med. Ass. 283:1460–8.CrossRefGoogle Scholar
  26. Lucero, M.G., Dulalia, V.E., Parreno, R.N., Lim-Quianzon, D.M., Nohynek, H., Mäkelä, H., and Williams, G. (2004). Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Syst. Rev. 4:CD004977.Google Scholar
  27. Lucero M.G., Puumalainen T., Ugpo J.M., Williams G., Käyhty H., Nohynek, H. (2004) Similar antibody concentrations in Filipino infants at age 9 months, after 1 or 3 doses of an adjuvanted, 11-valent pneumococcal diphtheria/tetanus-conjugated vaccine: a randomized controlled trial. J Infect Dis. 189:2077–84.PubMedCrossRefGoogle Scholar
  28. Lucero, M.G. Update on the Philippines ARIVAC effectiveness study of an 11-valent pneumococcal conjugate vaccine (11-PCV). (2005). Global Vaccine Research Forum Conference Abstract Book, Salvador de Bahia, Brazil, June 13, 2005.Google Scholar
  29. Madhi, S.A., Kuwanda, L., Cutland, C., Klugman, K.P. (2005). The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and-uninfected children. Clin. Infect. Dis. 40:1511–18.PubMedCrossRefGoogle Scholar
  30. Madhi, S.A., Heera, J.R., Kuwanda, L., and Klugman, K.P. (2005). Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia. PLoS Med. 2:e38.PubMedCrossRefGoogle Scholar
  31. Madhi S.A., Klugman K.P.; Vaccine Trialist Group. (2004). A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. 10:811–13.PubMedCrossRefGoogle Scholar
  32. Melegaro, A., and Edmunds, W.J. (2004). Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 22:4203–14.PubMedCrossRefGoogle Scholar
  33. Mulholland, E.K., Hilton, S., Adegbola, R.A., Usen, S., Oparaugo, A., Omosigho, C., Weber, M., Palmer, A., Schneider, G., Jobe, K., Lahai, G., Jaffar, S., Secka, O., Lin, K., Ethevenaux, C., and Greenwood, B. (1997). Randomized trial of Haemophilus influenzae type b-tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet. 349:1191–7.PubMedCrossRefGoogle Scholar
  34. O’Brien, K.L., Dagan, R. (2003). The potential indirect effect of conjugate pneumococcal vaccines. Vaccine. 21:1815–25.PubMedCrossRefGoogle Scholar
  35. O’Brien, K.L., Moulton, L.H., Reid, R., Weatherholtz, R., Oski, J., Brown, L., Kumar, G., Parkinson, A., Hu, D., Hackell, J., Chang, I., Kohberger, R., Siber, G., Santosham, M. (2003). Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet. 362:355–61.PubMedCrossRefGoogle Scholar
  36. O’Brien, K.L., Nohynek, H., the WHO Pneumococcal Vaccine Trials Carriage Working Group (2003). Report from a WHO Working Group: Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr. Infect. Dis. J. 22:133–40.PubMedCrossRefGoogle Scholar
  37. Okeke, I.N., Laxminarayan, R., Bhutta, Z.A., Duse, A.G., Jenkins, P., O’Brien, T.F., Pablos-Mendez, A., and Klugman, K.P. (2005). Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet. Infect. Dis. 5:481–93.PubMedCrossRefGoogle Scholar
  38. Pebody, R.G., Leino, T., Nohynek, H., Hellenbrand, W., Salmaso, S., and Ruutu, P. (2005). Pneumococcal vaccination policy in Europe. EuroSurveillance Monthly. 10:10 (Epub).Google Scholar
  39. Peltola, H., and Jaakkola, M. (1988). C-reactive protein in early detection of bacteremic versus viral infections in immunocompetent and compromised children. J. Pediatr. 113:641–6.PubMedCrossRefGoogle Scholar
  40. Pilishvili, T., Farley, M., Vazquez, M., Reingold, A., Nyquist, A., and Stefanek, K. Effectiveness of heptavalent pneumococcal conjugate vaccine in children. In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. Chicago, IL: American Society for Microbiology; 2003. p. 285.Google Scholar
  41. Prat, C., Dominguez, J., Rodrigo, C., Gimenez, M., Azuara, M., Jimenez, O., Gali, N., and Ausina, V. (2003). Procalcitonin, C-reactive protein and leukocyte count in children with lower respiratory tract infection. Pediatr. Infect. Dis. J. 22:963–7.PubMedCrossRefGoogle Scholar
  42. Prymula, R., Peeters, P., Chrobok, V., Kriz, P., Novakova, E., Kohl, I., Lommel, P., Poolman, J., Prieels J-P., Schuerman, L. (2005). An eleven-valent pneumococcal-protein D conjugate (11Pn-PD) vaccine protects against otitis caused by both pneumococci or Haemophilus influenzae. European Society for Paediatric Infectious Disease abstract book, Valencia, Spain, May 2005.Google Scholar
  43. Scott, J.A., Mlacha, Z., Nyiro, J., Njenga, S., Lewa, P., Obiero, J., Otieno, H., Sampson, J.S., and Carlone, G.M. (2005). Diagnosis of invasive pneumococcal disease among children in Kenya with enzymelinked immunosorbent assay for immunoglobulin G antibodies to pneumococcal surface adhesion A. Clin. Diagn. Lab. Immunol. 12:1195–201.PubMedCrossRefGoogle Scholar
  44. Smith, T., Lehmann, D., Montgomery, J., Gratten, M., Riley, I.D., and Alpers, M.P. (1993). Acquisition and invasiveness of different serotypes of Streptococcus pneumoniae in young children. Epidemiol. Infect. 1:27–39.CrossRefGoogle Scholar
  45. Syrjänen, R., Auranen, K., Leino, T., Kilpi, T., and Mäkelä, P.H. (2005). Pneumococcal acute otitis media in relation to pneumococcal nasopharyngeal carriage. Pediatr. Infect. Dis. J. 24:801–6.PubMedCrossRefGoogle Scholar
  46. Vuori-Holopainen, E., Salo, E., Saxen, H., Hedman, K., Hyypiä, T., Lahdenperä, R., Leinonen, M., Tarkka, E., Vaara, M., and Peltola, H. (2002). Etiological diagnosis of childhood pneumonia by use of transthoracic needle aspiration and modern microbiologicalmethods. Clin. Infect. Dis. 34:583–90.PubMedCrossRefGoogle Scholar
  47. Vuori-Holopainen, E., and Peltola, H. (2001). Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. Clin. Infect. Dis. 32:715–26.PubMedCrossRefGoogle Scholar
  48. World Health Organization Pneumonia Vaccine Trial Investigators’ Group (2001). Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. WHO/V&B/01.35, Geneva.Google Scholar
  49. Wright, A.E., and Morgan, W.P. (1914). Observations on prophylactic inoculation against pneumococcal infections, and on the results which have been achieved by it. Lancet. i, 1–10.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Hanna Nohynek
    • 1
  1. 1.Department of Vaccines Clinical UnitNational Public Health InstituteHelsinkiFinland

Personalised recommendations